SGLT2抑制剂与肾结石风险
本研究利用丹麦健康登记数据,对40岁及以上新使用SGLT2抑制剂或GLP1受体激动剂者进行倾向评分匹配队列研究,发现SGLT2抑制剂组肾结石发生率显著低于GLP1 RA组,且复发风险也降低。
要点
- SGLT2抑制剂组肾结石发生率为2.0/1000人年,GLP1 RA组为4.0/1000人年。
- SGLT2抑制剂与肾结石风险降低相关(HR 0.51, 95%CI 0.37-0.71)。
- 有肾结石病史者中,SGLT2抑制剂也降低复发风险(HR 0.68, 95%CI 0.48-0.97)。
核心结论
- 开始SGLT2抑制剂治疗与肾结石发生和复发风险显著降低相关。
研究设计与样本
- 基于丹麦健康登记数据的活性对照新用户队列研究,纳入2012年11月11日至2018年12月31日期间40岁及以上新使用SGLT2抑制剂或GLP1 RA的个体,经倾向评分1:1匹配后形成12,325对患者。
主要发现
- SGLT2抑制剂组肾结石发生率为2.0/1000人年,GLP1 RA组为4.0/1000人年,率差-1.9/1000人年(95%CI -2.8, -1.0),HR 0.51(95%CI 0.37, 0.71)。
- 在731对有肾结石病史的患者中,复发肾结石率差为-17/1000人年(95%CI -33, -1.5),HR 0.68(95%CI 0.48, 0.97)。
临床怎么用
- 对于合并肾结石风险的2型糖尿病患者,SGLT2抑制剂可能带来降低肾结石发生和复发的额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) may reduce nephrolithiasis risk by increasing urine flow. We aimed to investigate whether initiation of SGLT2I was associated with reduced nephrolithiasis risk. METHODS: We conducted an active-comparator new-user cohort study using the Danish health registries in the period 11 November 2012 to 31 December 2018. Individuals aged ≥40 years initiating SGLT2Is or glucagon-like peptide-1 receptor agonists (GLP1 RAs) were followed from treatment initiation until an inpatient or outpatient diagnosis of nephrolithiasis, death, emigration or end of study. New users of SGLT2Is were matched 1:1 on propensity scores to new users of GLP1 RAs. In supplementary analyses, risk of recurrent nephrolithiasis was assessed in individuals with a history of nephrolithiasis before treatment initiation. RESULTS: We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate difference of -1.9 per 1000 person-years (95% CI -2.8, -1.0) and an HR of 0.51 (95% CI 0.37, 0.71). For recurrent nephrolithiasis (n = 731 patient pairs), the rate difference was -17 per 1000 person-years (95% CI -33, -1.5) and the HR was 0.68 (95% CI 0.48, 0.97). CONCLUSIONS/INTERPRETATION: Initiation of treatment with SGLT2Is was associated with a clinically significant reduced risk of incident and recurrent nephrolithiasis.
引用
- Kristensen KB, Henriksen DP, Hallas J, et al. Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia. 2021. PMID: 33715024. doi:10.1007/s00125-021-05424-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。